Skip to main content

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

Active, not recruiting · Phase 3 · NCT07003984

Conditions: Chikungunya Virus

At a glance

Research payments reported, 2025
$704,398
U.S. investigators named
9
Sites paid
11
Planned or actual enrollment
720

About the trial

Sponsor
Bavarian Nordic
Tested
CHIKV VLP vaccine (biological), Placebo (biological)
Dates
Started 2025-06-05; completion 2028-09
Results posted
Not yet

The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to \<12 years of age.

From ClinicalTrials.gov, last updated 2026-09-30. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Bavarian Nordic A/s reported $704,398 in research payments for this study in 2025 (475 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Velocity Clinical Research $219,031
  • Acevedo Clinical Research Associates $196,805
  • Hope Research Network $91,067
  • Ark Clinical Research $59,813
  • Tekton Research Inc $48,618
  • Advarra Inc $43,722
  • Acevedo Clinical Research Associates - Clinical Trial Center $28,064
  • $13,025
  • Interspond LLC $1,483
  • Meridian Clinical Research LLC $1,271
  • Cincinnati Children's Hospital Medical Center, OH $750
  • Emerson Clinical Research Institute- Dc $749

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.